Results 171 to 180 of about 239,171 (312)

Experimental bacillary cirrhosis of the liver [PDF]

, 1901
L. Hektoen
openalex   +1 more source

Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis

Hepatology, EarlyView., 2022
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr, Benedikt Kaufmann, Maria Eugenia Inzaugarat, Theresa Maria Holtmann, Lukas Geisler, Jana Hundertmark, Marlene Sophia Kohlhepp, Laela M. Boosheri, Daisy R. Chilin‐Fuentes, Amanda Birmingham, Kathleen M. Fisch, Joel D. Schilling, Sven H. Loosen, Christian Trautwein, Christoph Roderburg, Münevver Demir, Frank Tacke, Hal M. Hoffman, Ariel E. Feldstein, Alexander Wree   +19 more
wiley   +1 more source

Cirrhosis of Liver [PDF]

Proceedings of the Royal Society of Medicine, 1910
openaire   +3 more sources

Guideline‐directed medical therapy rates in heart failure patients with reduced ejection fraction in a diverse cohort

ESC Heart Failure, EarlyView.
Abstract Aims Guideline‐directed medical therapy (GDMT) is recommended for all patients with heart failure with reduced ejection fraction (HFrEF). Despite this, little data exist describing GDMT use in diverse, real‐world populations including the use of vasodilators, prescribed primarily to Black populations.
Natalia C. Berry, Yi‐Shin Sheu, Karen Chesbrough, R. Clayton Bishop, Suma Vupputuri   +4 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Hepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente   +7 more
wiley   +1 more source

Studies on Cirrhosis of the Liver

, 1959
Takashi Nakamura, Shozo Nakamura, Masamitsu Watanabe, Toshimi Suzuki, Katuhiko Tokita, Toru Kimura, Tadashi Sato, Taketsugu Kaneko   +7 more
openalex   +4 more sources

Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study

Surgery Open Science
Aims: To evaluate the efficacy of re-resection in recurrent hepatocellular carcinoma (rHCC), identify prognostic factors, and provide clinical guidance.
Qi Fan, MM, Pengcheng Wei, MM, Delin Ma, MD, Qian Cheng, MD, Jie Gao, MD, Jiye Zhu, MD, Zhao Li, MD   +6 more
doaj  

Clinical Remarks on Hypertrophic Cirrhosis of the Liver with Bronzing of the Skin: Haemochromatosis [PDF]

, 1899
William Osler
openalex   +1 more source

Cirrhosis of Liver [PDF]

Proceedings of the Royal Society of Medicine, 1921
openaire   +3 more sources